Clinical Trial Update: Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients [Phase 2]

View source ↗

Summary

Phase II trial of axitinib (AG-013736) in elderly patients with glioblastoma multiforme has been terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: University of Cincinnati | Conditions: Glioblastoma Multiforme | Phase 2 | Status: TERMINATED | Results posted: 2017-09-19